InVivo Therapeutics Holdings Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InVivo Therapeutics Holdings Corp.
Venture Funding Deals: Gotham Raises $54m To Advance Epitranscriptomics
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.
Inside The Spinal Cord: InVivo Therapeutics Looks To Reverse Injury, Leverage Regulatory Reforms
InVivo Therapeutics is looking to build on a breakthrough in understanding the pathophysiology of spinal cord injury to bring the first device to market for partially reversing the debilitating condition. The firm is dealing with a cautious FDA in its pivotal-trial development, but also looking to leverage a new US policy for humanitarian-use devices to expedite its path to market expansion.
Execs On The Move, September 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Medtech Execs On The Move, August 2015
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
- Other Names / Subsidiaries
- Design Source, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.